The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis

Data on the risk of adverse events (AEs) and disease flares in autoimmune rheumatic diseases (ARDs) after the third dose of COVID-19 vaccine are scarce. The aim of this multicenter, prospective study is to analyze the clinical and immunological safety of BNT162b2 vaccine in a cohort of rheumatoid ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Picchianti Diamanti, Andrea, Navarra, Assunta, Cuzzi, Gilda, Aiello, Alessandra, Salemi, Simonetta, Di Rosa, Roberta, De Lorenzo, Chiara, Vio, Daniele, Sebastiani, Giandomenico, Ferraioli, Mario, Benucci, Maurizio, Li Gobbi, Francesca, Cantini, Fabrizio, Polidori, Vittoria, Simmaco, Maurizio, Cialdi, Esmeralda, Scolieri, Palma, Bruzzese, Vincenzo, Nicastri, Emanuele, D’Amelio, Raffaele, Laganà, Bruno, Goletti, Delia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045021/
https://www.ncbi.nlm.nih.gov/pubmed/36979666
http://dx.doi.org/10.3390/biomedicines11030687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045021/
https://www.ncbi.nlm.nih.gov/pubmed/36979666
http://dx.doi.org/10.3390/biomedicines11030687

Ejemplares similares